Npbwr1 signaling mediates fast antidepressant action

Area of Science:

• Neuroscience
• Molecular Psychiatry
• Pharmacology

Background:

• Chronic stress is a significant risk factor for depression, a leading cause of disability.
• Current antidepressants have limitations, including slow onset, side effects, and low efficacy, highlighting the need for novel therapeutic targets.
• Understanding the molecular mechanisms underlying stress-induced depression is crucial for developing effective treatments.

Purpose of the Study:

• To identify novel molecular targets involved in the regulation of depressive-like behaviors.
• To investigate the role of the neuropeptides B and W receptor 1 (Npbwr1) in the context of chronic stress and depression.
• To evaluate the therapeutic potential of targeting Npbwr1 for rapid antidepressant effects.

Main Methods:

• Utilized a mouse model of chronic stress to assess depressive-like behaviors.
• Measured Npbwr1 expression in the nucleus accumbens of stressed mice and postmortem in human depression samples.
• Employed viral-mediated gene transfer to establish a causal link between Npbwr1, neuronal morphology, and behavior.
• Administered a synthetic Npbwr1 antagonist (CYM50769) and assessed its behavioral and molecular effects.

Main Results:

• Npbwr1 expression was elevated in the nucleus accumbens of chronically stressed mice and in postmortem brain samples from depressed patients.
• Viral-mediated manipulation of Npbwr1 causally influenced depressive-like behaviors, dendritic spine morphology, and brain-derived neurotrophic factor (Bdnf) levels.
• Single-dose administration of the Npbwr1 antagonist CYM50769 rapidly ameliorated depressive-like behaviors and modulated Bdnf levels.
• CYM50769 demonstrated selectivity, good tolerability, and sustained effects for up to 7 days.

Conclusions:

• Npbwr1 is a critical regulator of depressive-like symptoms and a potential molecular link between chronic stress and depression.
• Targeting Npbwr1 with antagonists like CYM50769 offers a promising strategy for the development of fast-acting antidepressants.
• These findings provide new insights into the neurobiology of mood disorders and suggest a novel therapeutic avenue.